Back to today’s briefing

Story perspectives

Breakthrough Vaccine Doubles Liver Cancer Survival Time

8/30/2025

32 6

Summary

Story summary

A University of Birmingham clinical trial tested dendritic cell (DC) vaccines for liver cancer treatment.
Patients receiving the DC vaccine experienced a median progression-free survival (PFS) of 18.6 months, compared to 10.4 months for non-recipients.
The trial included 48 patients and showed improved outcomes, suggesting the need for further research.

1 of 1

Story summary

A University of Birmingham clinical trial tested dendritic cell (DC) vaccines for liver cancer treatment.
Patients receiving the DC vaccine experienced a median progression-free survival (PFS) of 18.6 months, compared to 10.4 months for non-recipients.
The trial included 48 patients and showed improved outcomes, suggesting the need for further research.